Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Analysis from the American College of Rheumatology RISE Registry

• Published in: Arthritis care & research (2010) 2024-02, Vol.76 (2), p.259-264
• Main Authors: Sattui, Sebastian E., Xie, Fenglong, Wan, Zihan, Clinton, Cassie, Domsic, Robyn T., Curtis, Jeffrey R.
• Format: Article
• Language: English
• Subjects: Aged; Antirheumatic Agents - therapeutic use; Comorbidity; Congestive heart failure; Female; Giant Cell Arteritis - drug therapy; Glucocorticoids; Glucocorticoids - therapeutic use; Humans; Hyperlipidemia; Immunomodulation; Informatics; Ischemia; Male; Polymyalgia rheumatica; Polymyalgia Rheumatica - diagnosis; Polymyalgia Rheumatica - drug therapy; Polymyalgia Rheumatica - epidemiology; Rheumatology; Steroids; United States - epidemiology
• ISSN: 2151-464X; 2151-4658; 2151-4658
• DOI: 10.1002/acr.25216

Objective This study describes the demographics, comorbidities, and treatment patterns in a national cohort of patients with polymyalgia rheumatica (PMR) who received care from rheumatology providers. Methods Patients with PMR were identified in the American College of Rheumatology Rheumatology Informatics System for Effectiveness registry from 2016 to 2022. Use of glucocorticoids and immunomodulatory antirheumatic medications used as steroid‐sparing agents were examined overall and in a subgroup of patients new to rheumatology practices, the majority with presumed new‐onset PMR. In these new patients, multivariate logistic regressions were performed to identify factors associated with persistent glucocorticoid and steroid‐sparing agent use at 12 to 24 months. Results A total of 26,102 patients with PMR were identified, of which 16,703 new patients were included in the main analysis. Patients were predominantly female (55.8%) and White (46.7%), with a mean age of 72.0 years. Hypertension (81.2%), congestive heart failure (52.4%), hyperlipidemia (41.3%), and ischemic heart disease (36.0%) were the most prevalent comorbidities. At baseline, 92.3% of patients were on glucocorticoids, and only 13.1% were on a steroid‐sparing agent. At 12 to 24 months, most patients remained on glucocorticoids (63.8%). Although there was an increase in use through follow‐up, antirheumatic medications were prescribed only to a minority (39.0%) of patients with PMR. Conclusion In this large US‐based study of patients with PMR receiving rheumatology care, only a minority of patients were prescribed steroid‐sparing agents during the first 24 months of follow‐up; most patients remained on glucocorticoids past one year. Further identification of patients who would benefit from steroid‐sparing agents and the timing of steroid‐sparing agent initiation is needed.